Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose leukemia has come back after a stem cell transplant from a donor, shown by leukemia cells reappearing in the blood or bone marrow, or in other parts of the body, or through specific lab test results.
- People whose bone marrow testing has found a specific gene change called C-KIT D816 or C-KIT N822 mutation.
- People whose leukemia has a specific gene abnormality called CBFB::MYH11 or RUNX1::RUNX1T1 fusion gene.
- People who are reasonably well and able to carry out daily activities, based on a standard health performance scale scored at 0, 1, or 2 out of 4.
- People whose liver, kidneys, and heart and lung function meet certain minimum levels, as measured by blood tests and scans taken within the 2 weeks before joining the trial (confirm specific values with trial site).
- People who agree to take part voluntarily, sign a consent form, and are able to follow and complete all parts of the trial.
Who may not be able to join:
- People with a known allergy to medicines in the same family as KIT inhibitor drugs.
- People who have previously been treated with a drug called Midostaurin.
- People who have previously been treated with a C-KIT inhibitor targeted specifically at their mutation and whose disease got worse while on that treatment.
- People whose leukemia has a gene change called FLT3-ITD mutation at a significant level (a low gene ratio may be acceptable — confirm with trial site).
- People who are currently infected with HIV, or who have an active hepatitis B or hepatitis C infection.
- People who have serious uncontrolled conditions such as heart or blood vessel disease, blood clotting disorders, connective tissue diseases, or severe infections.
- People who have uncontrolled active graft-versus-host disease (a condition where donor cells attack the body after a transplant).
- People whose leukemia has spread to the central nervous system (the brain and spinal cord).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, China
Phone: 15122538107
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-month ORR after induction therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.